Q-omics provides the consensus-scored ZBTB18 profile across patient tissues and cancer cell-line models. ZBTB18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB18 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZBTB18 RNA expression shows 20,913 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where ZBTB18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB18 survival associations across molecular data types. ZBTB18 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB18 RNA expression–survival associations across cancer types. High ZBTB18 expression shows unfavorable associations in MESO, but favorable associations in KIRC, LUAD, LGG, BLCA and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB18 RNA expression.
This table summarizes ZBTB18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB18 shows lower tumor expression in KICH, BLCA and LUSC and higher tumor expression in COAD, KIRP and LIHC. The COAD box plot shows higher ZBTB18 RNA expression in tumor versus normal tissue (log2 FC = +1.033, t-test p < 0.001).
This table shows molecular features associated with ZBTB18 in patient tissues and cancer cell lines. In patient samples, ZBTB18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
